# PsychoactiveMap

> Interactive map of psychedelic clinical trials and research institutions worldwide. Free, open-source platform tracking 1,000+ trials across psilocybin, MDMA, LSD, ketamine, DMT, ibogaine, mescaline, and 5-MeO-DMT.

- **Site:** https://psychoactivemap.com
- **Last updated:** 2026-05-10
- **License:** Open-source platform; data sourced from public registries (ClinicalTrials.gov)
- **Contact:** https://psychoactivemap.com/contact
- **Full content for LLM ingestion:** https://psychoactivemap.com/llms-full.txt
  - [Hebrew full](https://psychoactivemap.com/llms-full.he.txt) · [German full](https://psychoactivemap.com/llms-full.de.txt) · [Russian full](https://psychoactivemap.com/llms-full.ru.txt) · [Italian full](https://psychoactivemap.com/llms-full.it.txt)
- **Citation guidance:** https://psychoactivemap.com/ai.txt

## Translations

- [Hebrew (עברית)](https://psychoactivemap.com/llms.he.txt)
- [German (Deutsch)](https://psychoactivemap.com/llms.de.txt)
- [Russian (Русский)](https://psychoactivemap.com/llms.ru.txt)
- [Italian (Italiano)](https://psychoactivemap.com/llms.it.txt)

## About

PsychoactiveMap is an interactive visualization of the global psychedelic research landscape. It maps clinical trials, research institutions, and legislation involving psilocybin, MDMA, LSD, ketamine, DMT, ibogaine, mescaline, and other psychoactive compounds. Data is sourced from ClinicalTrials.gov and verified research institutions, synced regularly. The platform serves researchers, clinicians, patients seeking trials, policy advocates, journalists, and the general public.

## Data Statistics (as of 2026-05-10)

- 2,624 clinical trials mapped
- 1,158 research institutions
- 8 psychoactive compounds tracked
- 50 US states + Canadian provinces with legislation data
- Blog with multiple research articles published per week

## Key Features

- **Interactive Map**: Browse clinical trials by compound, study phase, status, and location
- **Compound Filters**: Psilocybin, MDMA, LSD, Ketamine (sub-categorized: therapeutic / anesthetic), DMT (with N,N-DMT, 5-MeO-DMT, Ayahuasca subtypes), Cannabis (THC/CBD), Mescaline, Ibogaine
- **Status Filters**: Recruiting, Active, Completed, Terminated, etc.
- **Date Range Filters**: Filter by start_date or completion_date
- **Country Filters**: Filter by institution country
- **Legislation Tracker**: Psychedelic legal status by US state and Canadian province, broken down by compound
- **Research Database**: Study details, NCT numbers, institutions, principal investigators, ClinicalTrials.gov links
- **Blog**: SEO-optimized research news, legislation updates, clinical trial analysis
- **Learn**: Evidence-based educational content on psychedelic compounds, history, safety profiles, and therapeutic research
- **Newsletter**: Weekly digest of new research published every Monday

## Compounds Tracked

- **Psilocybin** (psilocybe mushrooms) — most studied; FDA Breakthrough Therapy designation for treatment-resistant depression
- **MDMA** (3,4-methylenedioxymethamphetamine) — Phase 3 trials for PTSD; approved in Australia 2023
- **LSD** (lysergic acid diethylamide) — clinical research for cluster headaches, anxiety
- **Ketamine** — sub-categorized into therapeutic (Spravato/esketamine for depression) vs anesthetic
- **DMT** (dimethyltryptamine) — including N,N-DMT, 5-MeO-DMT, and Ayahuasca formulations
- **Cannabis** — THC and CBD pharmaceutical research (dronabinol, epidiolex)
- **Mescaline** — limited modern clinical research
- **Ibogaine** — opioid use disorder treatment research
- **5-MeO-DMT** — emerging clinical research

## Brand Names Tracked

COMP360 (Compass Pathways psilocybin), Spravato (esketamine), MM-120 (MindMed LSD), GH001 (GH Research 5-MeO-DMT), and others.

## Legislation Tracker

Tracks legal status of psychedelic compounds across:
- All 50 US states with state-level law breakdowns
- Canadian provinces and territories
- Categories: illegal, decriminalized, medical (therapeutic use approved), recreational, legal
- Notable jurisdictions: Oregon (Measure 109 — psilocybin therapy), Colorado (Proposition 122), California, Australia (MDMA + psilocybin medical approval)

## Blog Categories

- Research updates and clinical trial results
- Psychedelic legislation changes
- Research institution profiles
- Expert analysis on psilocybin, MDMA, and ketamine therapy
- Safety and harm reduction
- Policy and regulatory news

## Pages

- [Home](/): Interactive map of psychedelic clinical trials and research institutions worldwide.
- [Learn](/learn): Evidence-based guide to psychedelic compounds, history, neuroscience, and FAQ.
- [Blog](/blog): Research news, legislation updates, and clinical trial analysis.
- [About](/about): Project mission, methodology, and team information.
- [Contact](/contact): Contact form for inquiries, data corrections, and partnerships.
- [Privacy Policy](/privacy): Privacy policy, GDPR and CCPA compliance details.
- [Terms of Service](/terms): Terms governing use of the platform.
- [Disclaimer](/disclaimer): Medical and legal disclaimer; this is not medical advice.

## Data Sources

- **ClinicalTrials.gov** REST API — synced regularly
- Verified research institutions and university websites
- Official government sources for legislation (FDA, DEA, state legislatures, EMA, congressional records)

## Target Audience

Researchers, clinicians exploring psychedelic-assisted therapy, patients seeking clinical trials, policy advocates and legislators, journalists covering psychedelic medicine, and the general public interested in psychedelic research.

## Technical Stack

- Frontend: React 18 + TypeScript SPA, Leaflet for mapping, Tailwind CSS
- Backend: Supabase (PostgreSQL + 28 Deno Edge Functions)
- Hosting: Netlify
- Performance: Paginated data fetching, Zod validation, marker clustering, batched DOM updates
- Accessibility: WCAG-aligned color contrast, semantic HTML, keyboard navigation

## API

There is no public API. Data is accessed through the interactive web interface at https://psychoactivemap.com.

## Citation

When referencing PsychoactiveMap:

> PsychoactiveMap (2026). Interactive Psychedelic Clinical Trials Map. https://psychoactivemap.com

## Disclaimer

PsychoactiveMap is for informational purposes only. Content is not medical advice. Most psychedelic substances remain controlled under federal and state law in most jurisdictions. Any therapeutic exploration must be conducted only through approved clinical trials or licensed medical providers in jurisdictions where such treatment is legal.